Asymmetric Dimethyl-l-Arginine is a Biomarker for Disease Stage and Follow-Up of Pulmonary Hypertension Associated with Congenital Heart Disease

摘要: This study investigated the clinical value of plasma asymmetrical dimethyl-l-arginine (ADMA) level in diagnosis, staging, and treatment response congenital heart disease (CHD) patients with pulmonary arterial hypertension (PAH). was a single-center prospective observational 80 CHD patients. Plasma ADMA levels were measured by enzyme-linked immunosorbent assay. significantly increased PAH compared without (P < 0.01) healthy controls 0.001). In severe PAH, higher Eisenmenger’s syndrome (ES) than exhibiting low vascular resistance The correlated pressure 0.001) CHD. Severe identified cutoff 0.485 μmol/L specificity 82.8 % sensitivity 90 %. ES 0.85 0.05) 85.2 64.3 decreased after sildenafil therapy for 6 months before (0.91 ± 0.22 vs. 0.57 0.30, P 0.01). Our suggests that may be used as biomarker identifying CHD, assessing remodeling, evaluating to sildenafil.